Log In Sign up
The largest database of trusted experimental protocols

Sunitinib

Manufactured by Cell Signaling Technology
Visit Supplier
Sourced in United States

Sunitinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor. It targets multiple RTKs, including PDGFR, VEGFR, and c-Kit, which are involved in angiogenesis and cell proliferation.

Automatically generated - may contain errors

Lab products found in correlation

Thrombin, by Merck Group (2 mentions) Amg evos xl core digital microscope, by Thermo Fisher Scientific (2 mentions) Graphad prism, by GraphPad (2 mentions) Vatalanib, by Santa Cruz Biotechnology (2 mentions) Fibrinogen pbs solution, by Merck Group (2 mentions) Ebm 2, by Lonza (2 mentions) Erlotinib, by Cell Signaling Technology (1 mentions) Pdgf bb, by Cell Signaling Technology (1 mentions) Epidermal growth factor (egf), by Merck Group (1 mentions) Fr180204, by Merck Group (1 mentions) U0126, by Cell Signaling Technology (1 mentions)

3 protocols using sunitinib

1

Inhibition of PDGF and EGF Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sunitinib, erlotinib, U0126 (all purchased from Cell Signaling Technology, Danvers, MA, USA) and FR180204 (Sigma-Aldrich, St. Louis, MO, USA) were prepared as a 20 mM stock solution in dimethyl sulfoxide (DMSO) and stored at −20 °C. PDGF-BB (Cell Signaling Technology) was prepared at a concentration of 100 µg/mL in 20 mM citric acid (pH 3.0) supplemented with 0.8% BSA (bovine serum albumin) and stored at 4 °C. EGF (Sigma-Aldrich) was prepared at a concentration of 100 µg/mL in 10 mM HCl and stored at 4 °C. For the determination of proliferative activity, concentrations of protein kinase inhibitors (PKIs) ranging from 0.001 to 10 μM and PDGF-BB concentrations of 0.25 and 10 ng/mL were tested. For Western blot analyses, PKI concentrations ranging from 0.05 to 10 μM, PDGF-BB concentrations of 10 and 30 ng/mL and EGF concentrations of 40 and 100 ng/mL were used.
Sramek M., Neradil J., Macigova P., Mudry P., Polaskova K., Slaby O., Noskova H., Sterba J, & Veselska R. (2018). Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis. International Journal of Molecular Sciences, 19(9), 2599.
+ Open protocol
+ Expand
2

Inhibition of Angiogenic Sprouting in HUVEC Spheroids

Check if the same lab product or an alternative is used in the 5 most similar protocols
HUVEC were trypsinised and resuspended in EBM2 (Lonza) containing 2% foetal calf serum (FCS) at a concentration of 2.5×104 cells/ml. Methylcellulose was added at 0.25% (w/v) and 20μl drops were seeded in non-adherent dish. After inversion of the plate, suspended cells form a single spheroid containing approximately 500 cells. Treated spheroids were incubated with 1μM Sunitinib (Cell Signaling Technology, Inc) or 100nM Vatalanib (Santa Cruz) for 1hr prior to being embedded in a fibrin gel using 2.5mg/ml fibrinogen-PBS solution (Sigma) and 0.007 units of thrombin (Sigma). Once clotting occurred, EBM-2 containing 2% FCS was added with or without 1μM Sunitinib or 100nM Vatalanib. Spheroid photographs were taken after 24 hours using an AMG Evos XL Core digital microscope (Fisher Scientific, Loughborough, UK). Sprouting area was measured using ImageJ64 software and the results were analysed using Graphad Prism version 6 (Graphpad Software).
Behjati S., Tarpey P.S., Sheldon H., Martincorena I., Van Loo P., Gundem G., Wedge D.C., Ramakrishna M., Cooke S.L., Pillay N., Vollan H.K., Papaemmanuil E., Koss H., Bunney T.D., Hardy C., Joseph O.R., Martin S., Mudie L., Butler A., Teague J.W., Patil M., Steers G., Cao Y., Gumbs C., Ingram D., Lazar A.J., Little L., Mahadeshwar H., Protopopov A., Al Sannaa G.A., Seth S., Song X., Tang J., Zhang J., Ravi V., Torres K.E., Khatri B., Halai D., Roxanis I., Baumhoer D., Tirabosco R., Amary M.F., Boshoff C., McDermott U., Katan M., Stratton M.R., Futreal P.A., Flanagan A.M., Harris A, & Campbell P.J. (2014). Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature genetics, 46(4), 376-379.
+ Open protocol
+ Expand
3

Inhibition of Angiogenic Sprouting in HUVEC Spheroids

Check if the same lab product or an alternative is used in the 5 most similar protocols
HUVEC were trypsinised and resuspended in EBM2 (Lonza) containing 2% foetal calf serum (FCS) at a concentration of 2.5×104 cells/ml. Methylcellulose was added at 0.25% (w/v) and 20μl drops were seeded in non-adherent dish. After inversion of the plate, suspended cells form a single spheroid containing approximately 500 cells. Treated spheroids were incubated with 1μM Sunitinib (Cell Signaling Technology, Inc) or 100nM Vatalanib (Santa Cruz) for 1hr prior to being embedded in a fibrin gel using 2.5mg/ml fibrinogen-PBS solution (Sigma) and 0.007 units of thrombin (Sigma). Once clotting occurred, EBM-2 containing 2% FCS was added with or without 1μM Sunitinib or 100nM Vatalanib. Spheroid photographs were taken after 24 hours using an AMG Evos XL Core digital microscope (Fisher Scientific, Loughborough, UK). Sprouting area was measured using ImageJ64 software and the results were analysed using Graphad Prism version 6 (Graphpad Software).
Behjati S., Tarpey P.S., Sheldon H., Martincorena I., Van Loo P., Gundem G., Wedge D.C., Ramakrishna M., Cooke S.L., Pillay N., Vollan H.K., Papaemmanuil E., Koss H., Bunney T.D., Hardy C., Joseph O.R., Martin S., Mudie L., Butler A., Teague J.W., Patil M., Steers G., Cao Y., Gumbs C., Ingram D., Lazar A.J., Little L., Mahadeshwar H., Protopopov A., Al Sannaa G.A., Seth S., Song X., Tang J., Zhang J., Ravi V., Torres K.E., Khatri B., Halai D., Roxanis I., Baumhoer D., Tirabosco R., Amary M.F., Boshoff C., McDermott U., Katan M., Stratton M.R., Futreal P.A., Flanagan A.M., Harris A, & Campbell P.J. (2014). Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature genetics, 46(4), 376-379.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!